Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6

Emma von Witting, Javad Garousi, Sarah Lindbo, Anzhelika Vorobyeva, Mohamed Altai, Maryam Oroujeni, Bogdan Mitran, Anna Orlova, Sophia Hober, Vladimir Tolmachev

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Radionuclide molecular imaging is a promising tool that becomes increasingly important as targeted cancer therapies are developed. To ensure an effective treatment, a molecular stratification of the cancer is a necessity. To accomplish this, visualization of cancer associated molecular abnormalities in vivo by molecular imaging is the method of choice. ADAPTs, a novel type of small protein scaffold, have been utilized to select and develop high affinity binders to different proteinaceous targets. One of these binders, ADAPT6 selectively interacts with human epidermal growth factor 2 (HER2) with low nanomolar affinity and can therefore be used for its in vivo visualization. Molecular design and optimization of labeled anti-HER2 ADAPT has been explored in several earlier studies, showing that small changes in the scaffold affect the biodistribution of the domain. In this study, we evaluate how the biodistribution properties of ADAPT6 is affected by the commonly used maleimido derivatives of the macrocyclic chelators NOTA, NODAGA, DOTA and DOTAGA with the aim to select the best variants for SPECT and PET imaging. The different conjugates were labeled with 111In for SPECT and 68Ga for PET. The acquired data show that the combination of a radionuclide and a chelator for its conjugation has a strong influence on the uptake of ADAPT6 in normal tissues and thereby gives a significant variation in tumor-to-organ ratios. Hence, it was concluded that the best variant for SPECT imaging is 111In-(HE)3DANS-ADAPT6-GSSC-DOTA while the best variant for PET imaging is 68Ga-(HE)3DANS-ADAPT6-GSSC-NODAGA.

Original languageEnglish
Pages (from-to)109-120
Number of pages12
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume140
DOIs
Publication statusPublished - Jul 2019
Externally publishedYes

Keywords

  • ADAPT
  • DOTA
  • DOTAGA
  • Gallium-68
  • HER2
  • Indium-111
  • NODAGA
  • NOTA
  • Radionuclide imaging

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Selection of the optimal macrocyclic chelators for labeling with <sup>111</sup>In and <sup>68</sup>Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6'. Together they form a unique fingerprint.

Cite this